Kaipro Healthcare Pvt Ltd
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Tririga MG 1mg/500mg/0.2mg Tablet is a combination of anti-diabetic drugs used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels.
Tablet
Tririga MG 1mg/500mg/0.2mg Tablet is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tririga MG 1mg/500mg/0.2mg Tablet is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Tririga MG 1mg/500mg/0.2mg Tablet.
Tririga MG 1mg/500mg/0.2mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Tririga MG 1mg/500mg/0.2mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Tririga MG 1mg/500mg/0.2mg Tablet is a combination of three antidiabetic medicines:
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines alcohol or if you delay or miss a meal. Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain loss of appetite or yellowing of the eyes or skin (jaundice).
Tririga MG 1mg/500mg/0.2mg Tablet contains a combination of Glimepiride, Metformin and Voglibose. It is prescribed for the treatment of Type 2 diabetes mellitus (DM). This medication helps manage blood glucose levels in adults when combined with proper diet and exercise. Glimepiride reduces blood glucose by enhancing insulin release from the pancreas. Metformin lowers glucose production in the liver and improves insulin sensitivity. Voglibose acts as an alpha-glucosidase inhibitor, decreasing postprandial (after meal) glucose levels.
Possible side effects associated with using Tririga MG 1mg/500mg/0.2mg Tablet include hypoglycemia (low blood sugar), nausea, diarrhea, changes in taste, flatulence, stomach pain, headache, skin rash and respiratory tract infection.
Tririga MG 1mg/500mg/0.2mg Tablet use is contraindicated for patients with known allergies to any component or excipients of this medication. Its usage is also avoided in individuals with moderate to severe kidney disease and inflammatory bowel diseases such as colonic ulcerations or underlying metabolic acidosis including diabetic ketoacidosis.
No, combining Tririga MG 1mg/500mg/0.2mg Tablet with alcohol is not recommended. It may lower blood glucose levels (hypoglycemia) and increase the risk of lactic acidosis.
Yes, using Tririga MG 1mg/500mg/0.2mg Tablet can potentially lead to hypoglycemia (low blood sugar level). Symptoms of hypoglycemia include nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, and feeling anxious or shaky. This risk is higher when you miss meals or drinks alcohol, exercise excessively, or take other antidiabetic medications simultaneously.
Store Tririga MG 1mg/500mg/0.2mg Tablet in its original sealed container, tightly closed, as instructed on the packaging label. Do not dispose of unused medication and ensure it is inaccessible to children, pets, and other individuals.